|
Opioid Overdose Risk and Prevention
This is a 5 minute online activity included in the READINESS Opioid Learning Center "library".
This activity provides important information on opioid overdose – risks involved, prevention strategies & tips, and more to help you better understand how to combat opioid overdose and be better prepared in the event of an opioid overdose.
READINESS develops and hosts custom opioid eLearning centers for health systems, pharmacies, and organizations to support opioid stewardship and education ... |
|
|
How to Use Narcan (naloxone) Nasal Spray
This is a 5 minute online activity included in the READINESS Opioid Learning Center "library".
This activity provides important information on Narcan (naloxone) nasal spray – how to administer the medication, proper technique, and more to help you better understand how to use Narcan (naloxone) nasal spray.
READINESS develops and hosts custom opioid eLearning centers for health systems, pharmacies, and organizations to support opioid stewardship and education initiatives. Offer your com... |
|
|
Support Your Community with an Opioid eLearning Center Hosted by READINESS
READINESS develops and hosts custom opioid eLearning centers for health systems, pharmacies, and organizations to support opioid stewardship and education initiatives. Offer your community an intuitive and accessible eLearning center to support opioid education and awareness.
|
|
|
Zooming In on the Education and Empowerment of Patients in AMD Care
FDA-approved agents that target vascular endothelial growth factor (VEGF) constitute important elements of optimal management of AMD. Prior authorization (PA) requirements limit patient access to these therapies. Navigating the PA process can be frustrating for patients, and may result in treatment abandonment leading to suboptimal outcomes. Hence, there is a need for patients to become advocates of their treatment choice.
The final module of this CME Outfitters Snack series describes step ... |
|
|
Minimizing the Burden of Prior Authorization in AMD Through Actionable Strategies and Improved Communication
The development of anti–vascular endothelial growth factor (VEGF) agents has revolutionized the treatment of age-related macular degeneration (AMD). Nevertheless, optimal management of AMD is impeded by challenges in access to FDA-approved therapies. Step therapy, a type of prior authorization (PA) instituted by the payer, mandates that more cost-effective therapies be used before more expensive alternatives, in a stepwise approach. However, applying this strategy to vision-threatening disea... |
|
|
Keeping the Patient in the Center in AMD Care
Age-related macular degeneration (AMD) is the leading cause of legal blindness in adults over age 50, but the development of agents that target vascular endothelial growth factor (VEGF) has revolutionized its treatment. There are currently two FDA-approved agents (ranibizumab and aflibercept) and one off-label anti-VEGF agent (bevacizumab) being used to treat patients with AMD, and data from emerging anti-VEGF agents have also demonstrated efficacy in improving visual acuity. However, step the... |
|
|
7-Night Grenada Resort CME - Travel Medicine, Medical Cannabis for Pain Management, Concierge Medicine, Atrial Fibrillation, Osteoporosis, Dyslipidemia
Pink Gin Beach, St George's, Grenada |
|
|
11-Night Cook Islands & Society Islands CME AWAY™ Cruise
Papeete, Tahiti, Society Islands ● Huahine, Society Islands ● Aitutaki, Cook Islands ● Rarotonga, Cook Islands ● Bora Bora, Society Islands ● Taha'a, Society Islands ● Moorea, Society Islands |
|
|
10-Night Galapagos Islands CME AWAY™ Cruise - Family Medicine, Breast Cancer & Orthopedic Surgery
Quito, Ecuador ● Baltra ● Isla Daphne Grande ● Bahia Darwin ● El Barranco ● Seymour Norte ● Santiago Rabida ● Santa Cruz ● San Cristobal ● Punta Pitt ● Gardner Bay ● Punta Suarez ● Estacion Darwin ● Puerto Ayora ● Plazas Sur |
|
|
7-Night Alaska Dawes Glacier CME AWAY™ Cruise - From COPD to Migraines to Arthritis and More! An Interactive CME Program North of 60
Seattle, Washington ● Ketchikan, Alaska ● Endicott Arm ● Juneau, Alaska ● Skagway, Alaska ● Victoria, British Columbia |
|
|
Abdominal Pain, Celiac Disease, Pediatric GI, Emergency Medicine, Dysphagia, Post Nasal Drip and Thyroid Nodules and Eustachian Tube Dysfunction - Australia & New Zealand CME AWAY Cruise
Auckland, New Zealand • Tauranga (Bay Of Plenty), New Zealand • Wellington, New Zealand • Picton, New Zealand • Kaikoura, New Zealand • Akaroa, New Zealand • Dunedin (Port Chalmers), New Zealand • Stewart Island, New Zealand • Hobart (Tasmania), Australia • Melbourne, Australia • Eden, Australia • Sydney, Australia |
|
|
Live 2-Part Online Meeting Evolving Concepts in Anterior Segment Outcomes Tackling Ocular Surface Disease, Comanaging Premium IOL Patients, & Identifying New Treatments for Keratoconus Part 2
This live virtual forum is designed to educate optometrists on the use of new lens-based and corneal technologies that, combined with advances in ocular surface disease management, support premium visual outcomes in cataract and refractive surgery patients. |
|
|
Live 2-Part Online Meeting Evolving Concepts in Anterior Segment Outcomes Tackling Ocular Surface Disease, Comanaging Premium IOL Patients, & Identifying New Treatments for Keratoconus Part 1
This live virtual forum is designed to educate optometrists on the use of new lens-based and corneal technologies that, combined with advances in ocular surface disease management, support premium visual outcomes in cataract and refractive surgery patients. |
|
|
11-Night Spain, Portugal & Canary Islands CME AWAY™ Cruise
Southampton, England • Porto (Leixoes), Portugal • Lanzarote, Canary Islands • Tenerife, Canary Islands • Gran Canaria, Canary Islands • Lisbon, Portugal • Vigo, Spain |
|
|
14-Night Scandinavia & St. Petersburg CME AWAY™ Cruise - Palliative Care for Generalists & Updates on Infectious Diseases
Southampton, England ● Copenhagen, Denmark ● Stockholm, Sweden ● Helsinki, Finland ● St. Petersburg, Russia ● Berlin (Warnemunde), Germany ● Aarhus, Denmark |
|
|
10-Night Italy, Croatia & Montenegro CME AWAY™ Cruise - Gout, RA, Fibromyalgia, Lupus, Raynauds, Cannabinoids, Opioid Use Disorder & Other Addictions
Rome (Civitavecchia), Italy ● Corfu, Greece ● Split, Croatia ● Trieste, Italy ● Koper, Slovenia ● Dubrovnik, Croatia ● Kotor, Montenegro ● Naples, Italy |
|
|
7-Night Norwegian Fjords CME AWAY™ Cruise
Southampton, England ● Bergen, Norway ● Alesund, Norway ● Olden, Norway ● Stavanger, Norway |
|
|
10-Night Venice, Turkey & Greek Islands CME AWAY™ Cruise
Venice, Italy ● Katakolon, Greece ● Santorini, Greece ● Ephesus (Kusadasi), Turkey ● Mykonos, Greece ● Athens (Piraeus), Greece ● Chania (Souda), Crete, Greece ● Zakynthos, Greece |
|
|
14-Night Ireland & Iceland CME AWAY™ Cruise
Southampton, England ● St. Peter Port, Channel Island ● Cork (Cobh), Ireland ● Waterford (Dumore East), Ireland ● Dublin, Ireland ● Glasgow (Greenock), Scotland ● Akureyri, Iceland ● Reykjavik, Iceland ● Belfast, Northern Ireland |
|
|
nAMD and Imaging Modalities
This certified CME activity is designed for retina specialists and eye care professionals involved in the medical management of patients with retina disorders.
|
|
|
The Basics of Pigment Epithelial Detachment and the Latest in nAMD Therapies
This certified CME activity is designed for retina specialists and eye care professionals involved in the medical management of patients with retina disorders. |
|
|
The Basics of nAMD Treatment
This certified CME activity is designed for retina specialists and eye care professionals involved in the medical management of patients with retina disorders. |
|
|
Comanaging Premium IOL Patients: Presbyopia Correction
This expert discussion will review how to improve patient outcomes by managing presbyopia-correcting intraocular lenses (IOLs) in today’s optometric practice. This 1-hour program will review how to match patients with the appropriate IOL and optimize their outcomes. Program content will include evidence-based didactic presentations, interactive discussions, and relevant case presentation discussions. |
|
|
Neurotrophic Keratitis: New Approaches to Manage Disease and Improve Patient Satisfaction
CONTENT SOURCE
This continuing medical education (CME)/continuing education (CE) activity captures content from two webcasts.
ACTIVITY DESCRIPTION
Neurotrophic keratitis is a degenerative corneal disease characterized by decreased or absent corneal sensation, which can lead to epithelial breakdown, impairment of healing, and ultimately to the development of corneal ulceration, melting and perforation. Treating neurotrophic keratitis should be prompt and based on the stage and severity of ... |
|
|
Disease Prevalence and Advanced Imaging Modalities
This webcast featuring a dialogue and case studies with a retinal specialist and an optometrist and will review disease prevalence advanced diagnostic imaging pivotal treatment trials and challenging case studies.
Target Audience
This certified COPE activity is designed for optometrists involved in the management of patients with diabetes |
|
|
Diabetic Macular Edema Management
Diabetes is the leading cause of new cases of blindness among adults age 18 to 64 years, according to the Centers for Disease Control and Prevention’s 2020 National Diabetes Statistics Report. This activity reviews the management of patients with diabetic macular edema, with a focus on 1- and 2-year results of the Protocol T clinical trial. |
|
|
New Options in Glaucoma Pharmacology: Targeting the TM
New options have become available in recent years for the medical management of glaucoma. Drs. Khouri and Sawhney discuss the importance of individualized care for patients, with an emphasis on lowering IOP through enhancing trabecular meshwork outflow using novel therapies rather than surgical options as first-line treatment.
TARGET AUDIENCE
This certified CME/CE activity is designed for specialists and other allied eye care practitioners involved in the management of glaucoma and associa... |
|
|
Coordinated Care and the Complex Diabetic Retinopathy Patient
This webcast will feature content designed for the comanagement of patients with advanced diabetic retinopathy. Topics of discussion include stages of retinal disease optimal time for referral telemedicine and the importance of maintaining communication in addition to challenging case studies.
Target Audience
This certified COPE activity is designed for optometrists involved in the management of patients with diabetes. |
|
|
Corneal Disorders: Keratoconus and Corneal Collagen Crosslinking
This discussion will provide optometrists with a comprehensive 30-minute education program on how to improve patient outcomes by diagnosing and managing corneal disorders in today’s optometric practice. The course will focus on patient identification and the latest research results related to comanaging patients with keratoconus, including corneal crosslinking. Program content will include a set of evidence-based didactic presentations, interactive panel discussions, and relevant case pres... |
|
|
Corneal Disorders: Genetic Testing and Neurotrophic Keratitis
This expert discussion will provide optometrists with a comprehensive 15-minute education program on how to improve patient outcomes by diagnosing and managing corneal disorders in today’s optometric practice. The course will focus on patient identification and the latest research results related to comanaging patients with neurotrophic keratitis, including genetic testing. Program content will include a set of evidence-based didactic presentations, interactive panel discussions, and relev... |
|
|
Tackling Ocular Surface Disease: Treating Ocular Surface Diseases
This expert discussion will provide optometrists with a comprehensive 30-minute education program on how to improve patient outcomes by managing ocular surface disease (OSD) in today’s optometric practice. The course will review how to improve OSD treatment decisions. Program content will include a set of evidence-based didactic presentations, interactive discussions, and relevant case presentation discussions. |
|
|
Tackling Ocular Surface Disease: Diagnosing Dry Eye and MGD
This expert discussion will provide optometrists with a comprehensive 30-minute education program on how to improve patient outcomes by managing ocular surface disease (OSD) in today’s optometric practice. The course will demonstrate the impact of the ocular surface on visual quality and review how to improve OSD diagnostic decisions. Program content will include a set of evidence-based didactic presentations, interactive discussions, and relevant case presentation discussions. |
|
|
Comanaging Premium IOL Patients: Astigmatism Correction
This expert panel will review how to improve patient outcomes by managing presbyopia-correcting intraocular lenses (IOLs) in today’s optometric practice. This 1-hour program will review how to match patients with the appropriate IOL and optimize their outcomes. Program content will include evidence-based didactic presentations, interactive panel discussions, and relevant case presentation discussions. |
|
|
The Relationship Between Fluid and BCVA
This activity will review the latest data on how intraretinal fluid and subretinal fluid in the retinal pigment epithelium affects visual acuity in patients with neovascular macular degeneration.
PRIMARY AUDIENCE:
Retina specialists involved in the treatment and management of patients with retina disorders.
|
|
|
AMD Essentials and an RVO Review
This activity focuses primarily on studies that highlight all of the anti-VEGF dosing paradigms investigated in large, randomized clinical trials for the treatment of neovascular age-related macular degeneration plus two case presentations. A brief review of study results for retinal vein occlusion is also included.
PRIMARY AUDIENCE:
Retina specialists involved in the treatment and management of patients with retina disorders.
|
|
|
Gene Therapy: An Emerging Frontier in the Treatment of Neovascular Diseases
CONTENT SOURCE
This continuing medical education (CME) activity captures content from a roundtable discussion.
ACTIVITY DESCRIPTION
There is potential for gene therapy to effectively treat neovascular diseases and eliminate the significant treatment burden. This roundtable discussion includes a review of the latest data, potential utility, and remaining questions surrounding this novel approach for management of neovascular age-related macular degeneration (nAMD).
|
|
|
Ushering in a New Treatment Paradigm for Glaucoma: Updates on Novel Therapeutics and Disease-Modifying Treatments
CONTENT SOURCE
This continuing medical education (CME)/continuing education (CE) activity captures content from a live event.
ACTIVITY DESCRIPTION
Medical/topical therapy is the first-line choice for most physicians treating patients with primary open-angle glaucoma (POAG), yet some patients will have visual field loss despite adequate IOP control. This supplement focuses on the investigative agents that will help deliver treatment in a more consistent and patient-friendly manner. |
|
|
MGD Consensus Panel: Taking Aim at Meibomian Gland Dysfunction
CONTENT SOURCE
This continuing education activity captures content from a roundtable discussion.
ACTIVITY DESCRIPTION:
The following activity focuses on the rising awareness of meibomian gland dysfunction (MGD) and its impact on ocular surface disease.
TARGET AUDIENCE:
This educational activity is intended for optometrists. |
|
|
2nd Annual International OSD Review
A discussion of the progress of the DEWS II TFOS report particularly with a view on what has changed in practice and what more can be derived from the report. |
|
|
Neurotrophic Keratitis: Differential Diagnosis, Treatment Options, and Case Discussions
This CME webinar will highlight the various ways in which neurotrophic keratitis can present and will also include practical information on current and investigative treatment options. The program hosts will discuss challenging cases. |
|
|
A Look at the Glaucoma Armamentarium
This webinar presents the following learning objectives:
Identify the mechanisms of action as well as the efficacy and safety profiles of novel trabecular outflow medications.
Demonstrate proficiency in selecting appropriate therapies to achieve individualized patient-specific treatment goals.
Advocate for patients who would benefit from new drugs before they are incorporated into payors’ formularies. |
|
|
Tailoring Therapy to the Neovascular AMD Patient: Implementing Novel Treatment Strategies to Improve Outcomes
By 2040, an estimated 228 million people worldwide will be diagnosed with age-related macular degeneration (AMD). Treatment with anti-VEGF intravitreal injections has been shown to improve vision by 6 to 10 letters from baseline, but real-world results differ from clinical trial results. Therefore, it is clear that retina specialists need to be fully educated on the various treatment options to deliver the best patient care. |
|
|
New Pharmacotherapeutics for the Treatment of Glaucoma: Targeting the Trabecular Meshwork
CONTENT SOURCE
This continuing medical education (CME)/continuing education (CE) activity captures content from a roundtable discussion.
ACTIVITY DESCRIPTION
The development and commercialization of two new topical glaucoma drugs has renewed interest in medical therapy. In late 2017, after a 2-decade gap in glaucoma pharmacology innovation, two drugs in novel classes were approved for IOP reduction in eyes with ocular hypertension or open-angle glaucoma. These drugs lower IOP through uniq... |
|
|
Excisional Goniotomy for the Cataract Surgeon
This webinar will provide valuable information on how to incorporate certain microinvasive glaucoma surgery (MIGS) procedures into a cataract/refractive practice. |
|
|
Diagnosing, Treating, and Managing Scleritis in 2020
This work is based on a virtual roundtable discussion hosted by Evolve Medical Education LLC.
Although uncommon, scleritis is a dangerous immune-mediated disease that can potentially threaten the structural integrity of the eye and may be indicative of potentially life-threatening systemic vasculitis. Data on the genetic factors of scleritis is lacking, but it is thought that genes affecting systemic autoimmune diseases impact scleritis as well. Differentiating between episcleritis and scl... |
|
|
Navigating the World of Retina: Updates for the Newer Retina Specialist
Retinal disorders, including age-related macular degeneration (AMD) and diabetic macular edema (DME), can result in vision loss if not treated early and—in most cases—continuously. The need for newer retina specialists to be fully educated on the various treatment options remains crucial to delivering the best patient care. In addition, retina specialists new to practice must also navigate the business aspects of their clinics.
TARGET AUDIENCE
This certified CME activity is designed fo... |
|
|
The Latest in LASIK: Updates in Technology and Clinical Outcomes
This activity focuses on the recent innovations and associated developments in LASIK, including modern ablation profiles and modern diagnostics technologies, that can help to increase the level of visual outcomes patients can achieve postoperatively and can also help to further reduce LASIK complication rates. Such educational efforts are also necessary to ensure that surgeons and other eye care practitioners understand the tools available to them to offer patients the most customizable LASIK ... |
|
|
Postoperative Inflammation: Advances in Treatment
This webinar includes information and case based studies on the following learning objectives:
Identify the issues surrounding patient compliance with topical medications postoperatively.
Describe the benefits of intraoperative delivery of anti-inflammatory medications during cataract surgery.
Summarize the drug delivery properties of novel sustained release medications.
State how the latest federal government regulations on reimbursement will affect practices treating Medicare-eligib... |
|
|
Advances in Postoperative Anti-inflammatory Treatment
Despite the routine use of antibiotics, corticosteroids, and non-steroidal anti-inflammatory (NSAID) agents in postoperative ophthalmic surgical care, there are no controlled investigations to establish the optimal regimens for topical agents after cataract surgery. The individual surgeon decides whether to use any or all of these medications postoperatively.
Ongoing education about novel corticosteroids and technologies is warranted to ensure eye care providers can deliver the best patient... |
|
|
Understanding, Diagnosing, and Treating Neurotrophic Keratitis: An Overview
This webinar is for ophthalmologists who treat cornea disease. |
|